STAT Plus: A moment of truth arrives for CytoDyn’s Covid-19 drug. Don’t let spin obscure it
When results of the study read out in the next few weeks, the experimental drug leronlimab is unlikely to show meaningful benefit. Here's why.
Suscribirse a:
Enviar comentarios (Atom)
No hay comentarios:
Publicar un comentario